CPSE:NOVO BPharmaceuticals
Novo Nordisk Pediatric Oral GLP-1 Trial Opens New Franchise Questions
Novo Nordisk reported positive phase 3 results for oral semaglutide in children and adolescents with type 2 diabetes.
The company plans upcoming regulatory filings in the US and EU for oral Ozempic and Rybelsus based on these data.
The news centers on potential expansion of oral GLP-1 use into a younger patient population.
Novo Nordisk, traded as CPSE:NOVO B, is adding a fresh clinical catalyst to its diabetes franchise with positive phase 3 data for oral semaglutide in pediatric type 2...